Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study.

Takaaki TokitoOleksii KolesnikJens SørensenMehmet ArtacMartín Lázaro QuintelaJong-Seok LeeMaen HusseinMiklos PlessLuis Paz-AresLance LeopoldJeannie DanielMihaela MunteanuAyman SamkariLu XuCharles Butts

Published in: BMC cancer (2024)

ClinicalTrials.gov, NCT03322540. Registered 10/26/2017.

Keyphrases

double blind
placebo controlled
advanced non small cell lung cancer
clinical trial
phase iii
squamous cell carcinoma
small cell lung cancer
open label
study protocol
phase ii
epidermal growth factor receptor
randomized controlled trial